Pharmaceutical Technology

JANUARY 10, 2023

Many of the current existing therapies are often viewed by physicians as not optimal to addressing the needs of patients, and challenges remain such as improving patient compliance, safety profile, and addressing comorbidities of T2D. billion in sales in 2019, increasing to $136.2

Marketing 52

Marketing Physicians Leads Sales 52

Pharmaceutical Technology

MAY 23, 2023

In May 2021, Amgen’s Lumakras was approved for use in adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC). According to a consensus forecast from GlobalData’s Pharma Intelligence Centre, Lumakras, also known as sotorasib, has projected sales of $1.47 billion in 2029.

Pharma 52

Pharma Sales Pharmaceutical Patients 52

pharmaphorum

NOVEMBER 24, 2022

The phase 3 ESCAPE-TRD study in 676 patients revealed that significantly more of those treated with Spravato were able to achieve remission from symptoms of depression without a relapse over 32 weeks of follow-up compared to quetiapine. and 14.1%, respectively.

Sales 52

Sales Patients Competition Marketing 52

Pharmaceutical Technology

FEBRUARY 3, 2023

According to GlobalData’s Sales and Forecast Consensus database, Humira is anticipated to have garnered sales of $18.6 Based on GlobalData’s patient-based forecast models, RA and CD are the top two indications contributing to this value, accounting for around 45% and 14%, respectively, of Humira’s sales. billion in 2022.

Marketing 52

Marketing Sales Patients Physicians 52

Pharmaceutical Technology

JULY 8, 2022

Blincyto has provided a strong positive signal to demonstrate the clinical and commercial viability of BiTEs, with 2021 company-reported global sales of $542 million and GlobalData’s analyst consensus forecast projecting peak annual sales of $771 million by 2029, thereby sparking further industry interest in this field.

Safety 59

Safety Sales Marketing Patients 59

Pharmaceutical Technology

JULY 15, 2022

Over the next few years, biosimilars are expected to erode the sales of major originator insulin brands such as Sanofi’s Lantus (insulin glargine), Eli Lilly’s Humalog, and Novo Nordisk’s NovoLog. GlobalData is the parent company of Pharmaceutical Technology. Industry split over the pricing issues.

Manufacturing 131

Manufacturing Insurance Pharmaceutical Marketing 131

Pharmaceutical Technology

APRIL 4, 2023

of NSCLC patients with exon 19 and 21 mutations develop resistance mutations at C797S. According to GlobalData’s Pharma Intelligence Centre, Tagrisso is forecasted to have global sales of $8.19 billion in 2029. Up to 12.5% While Scorpion will lead the development of STX-721, Pierre Fabre will handle STX-241.

Food and Drug Administration 52

Food and Drug Administration Biopharma FDA Pharmaceutical 52

pharmaphorum

DECEMBER 20, 2022

Wedbush Securities recently forecast more than $1 billion in 2029 sales for ensifentrine in the US alone, assuming a launch in the first quarter of 2024, and said today the stock could easily reach $30. Shares in Verona popped on the news, rising more than 40% to approach $19.50 and drive the company’s market cap to almost $1.5

Pharma 57

Pharma Sales Leads Marketing 57

PM360

APRIL 7, 2023

Pharma, formulary decision-makers, and contracting specialists must now track exact dates when drugs became available, then track the difference between average sales price (ASP) and Maximum Fair Price (MFP) to ensure provider reimbursement is correct.” Impact Beyond Medicare The IRA won’t just impact negotiation with the government either.

Marketing 52

Marketing Pharma Manufacturing Healthcare 52

Pharmaceutical Technology

MAY 19, 2023

Rituxan received its first FDA approval in 1997 for the treatment of B-cell non-Hodgkin’s lymphoma (B-NHL) and reached peak global sales of $7.5bn in 2014. Rituximab biosimilars have since achieved notable commercial success, with global sales surpassing $900m collectively.

Sales 59

Sales Competition Marketing Patients 59

Pharmaceutical Technology

JUNE 13, 2023

The agent is being evaluated in relapsed/refractory (R/R) patients who have KMT2A-rearranged (KMT2ar) or NPM1-mutant (NPM1m) acute myeloid leukaemia (AML). Ziftomenib targets the menin-KMT2a protein-protein interaction that may occur in patients with KMT2ar or NPM1m genetic alterations. months for all patients achieving CRc.

Patients 52

Patients Sales Competition Safety 52

European Pharmaceutical Review

JANUARY 18, 2024

The company predicted this will be “driven by an increase in the patient share of dual orexin receptor antagonists (DORAs)”. In its report on the insomnia market published last month, GlobalData expected that sales for DORAs, which offer a new mechanism of action for the condition, will continue to grow at a CAGR of 8.6

Marketing 88

Marketing Sales Pharmacology Pharma 88

Pharmaceutical Technology

JUNE 12, 2023

In 2022, the FDA awarded VX-548 breakthrough therapy and fast-track designations for post-operative pain, and the drug is forecast to reach sales of $416m by 2029. A promising example includes Vertex Pharmaceuticals’s VX-548, a sodium channel subunit blocker. Six cannabinoids have recently completed or are undergoing Phase II trials.

Medical 143

Medical Prescription Management Manufacturing 143

Pharmaceutical Technology

MAY 17, 2023

Orphan drug designations are granted to drugs that target rare disorders with fewer than 200,000 patients in the US. Primary biliary cholangitis is a rare autoimmune disease where small bile ducts are injured by the patient’s own immune system. billion in 2029. The condition gradually worsens and can result in liver failure.

Food and Drug Administration 52

Food and Drug Administration FDA Pharmaceutical Prospecting 52